Beyond KEYNOTE-564 eligibility: A clinical decision aid to refine selection for adjuvant pembrolizumab in clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles